PRAMEing a picture of differentiation therapy for AML?

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2277-2279

  Redner, Robert L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; COREPRESSOR PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; NUCLEOPHOSMIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TIOGUANINE; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; DRUG EFFICACY; EVENT FREE SURVIVAL; GENE; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; LIGAND BINDING; NONHUMAN; OVERALL SURVIVAL; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, RETINOIC ACID; TRETINOIN;

EID: 84877090348     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0386     Document Type: Article

References (12)

1. Bullinger L, Schlenk RF, Gotz M, Botzenhardt U, Hofmann S, Russ AC, et al. PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17). Clin Cancer Res 2013;19:2562-71.
2. Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 2010;9:226.
3. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835-47. (Pubitemid 41345202)
4. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215. (Pubitemid 29220886)
5. Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci U S A 1993;90:7153-7. (Pubitemid 23222407)
6. Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther 2007;6:3081-90.
7. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fl udarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:2478-84. (Pubitemid 29181178)
8. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010;115:948-56.
9. Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. Hematol J 2002;3:49-55. (Pubitemid 34223916)
10. Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004;18:1798-803. (Pubitemid 39534320)
11. Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009;94:54-60.
12. Schlenk RF, Dohner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, et al. All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia - results of the AMLSG 07-04 Randomized Treatment Trial. Blood 2011;118:38-9.